New Product Update

 

Leading drug manufacturer Beximco Pharmaceuticals Ltd (BPL) has introduced new strength of etoricoxib, Ribox-120, for the management of pain associated with ankylosing spondylitis, acute gouty arthritis & dental procedure.

Leading drug manufacturer Beximco Pharmaceuticals Ltd. (“BPL” or “Beximco Pharma”) has introduced ten new products (eight generics) during January to March 2011.

Leading drug manufacturer Beximco Pharmaceuticals Ltd (BPL) has introduced new nasal spray for the proper management of allergic rhinitis and nasal congestion.

More than 7 million people are suffering from asthma and COPD in Bangladesh and the number is increasing day by day. Considering the fact Beximco Pharmaceuticals Ltd. (BPL), the leading-edge pharmaceutical manufacturer and the largest pharmaceutical exporter of Bangladesh has recently introduced 3 new respirator solutions for the effective treatment of Asthma and COPD.

Beximco Pharmaceuticals Ltd. (BPL or the company), the leading pharmaceutical manufacturer and the largest pharmaceutical exporter of Bangladesh, has launched two new HFA inhalers, Bexitrol- F and Bexitrol in the month of July 2009 for effective management of asthma and COPD patients. It is to be mentioned that Bexitrol-F, a combination inhaler, is first time locally manufactured in Bangladesh.

Leading drug manufacturer Beximco Pharmaceuticals Ltd (BPL) has introduced 4 new cardiovascular drugs for the proper management of hypertension, lipid profile and other cardiovascular diseases.

Beximco Pharmaceuticals Ltd. (BPL or the Company), the leading edge pharmaceutical manufacturer and the largest pharmaceutical exporter of Bangladesh celebrated its newly launched ophthalmic division named “Beximco Pharma Vision” with the Ophthalmologist community of the country on October 30, 2009 at Dhaka.

Considering the unavoidable CFC phase-out, leading drug manufacturer Beximco Pharma has continued its pioneering initiative in launching CFC-free HFA inhalers. With this introduction of three new CFC free inhalers on 5th March, 2010, we have strengthened our HFA MDIs portfolio for the effective management of Asthma and COPD. “BPL now has complete range of CFC free inhalers to treat all the steps of severity in asthma management.” said Mr. Rabbur Reza, Chief Operating Officer of Beximco Pharma. “BPL is now the single largest producer of MDIs in Bangladesh and the only company in Asia to contract manufactures a widely used inhaler product of a multi-national company in Bangladesh,” Reza added.

Leading drug manufacturer Beximco Pharmaceuticals Ltd (BPL) has introduced 3 new products for Insomnia, Respiratory & Urinary Tract Infections and for the prevention of Bronchospasm

The largest Metered Dose Inhaler (MDI) manufacturer of Bangladesh, Beximco Pharmaceuticals Limited (BPL) has launched a novel, new generation corticosteroid inhaler Cesonide® today (June 04, 2006) for the treatment of adults suffering from persistent asthma.